期刊文献+

表皮生长因子受体抑制剂所致皮肤毒性症状管理的最佳证据应用 被引量:5

The application of best evidence-informed practice of skin toxicity caused by EGFRIs
下载PDF
导出
摘要 目的 :将表皮生长因子受体抑制剂(EGFRIs)所致皮肤毒性的最佳证据应用于临床实践,提高护士在皮肤毒性症状管理中证据应用的依从性,降低患者皮肤毒性症状的发生率和严重程度,提高患者生活质量。方法:采用JBI循证护理中心的临床证据实践应用系统(PACES)的标准程序,获取JBI在线临床治疗及护理证据网络(COn NECT+)数据库中现有的相关最佳实践证据,制定相应审查标准。采用现场观察法、访谈、查阅护理病历收集数据。结果:第2轮审查中5条审查指标已达到100.00%,患者生活质量调查表得分从(25.18±17.29)分降低至(7.59±6.79)分(P=0.001)。结论 :EGFRIs所致的皮肤毒性症状管理的最佳证据应用能够规范护士的临床护理实践,提高患者生活质量。 Objective:To implementing best evidence-informed practice of skin toxicity caused by EGFRIs,to improve the nurses' compliance of skin toxicity symptom management,to decrease the incidence and severity of patients' skin toxicity,and to improve the patients' quality of life.Methods:We adopted the standard procedure of Practical Application of Clinical Evidence System(PACES) of JBI evidence-based nursing center,and obtained the best related practice evidence in the Clinical Online Network of Evidence for Care and Therapeutics(COn NECT+) database of JBI,and formulated corresponding review criteria.The data were collected by field observation,interviews,and medical records.Results:About 5 criterion in the second audit achieved 100.00% compliance.The patients' score of Skindex-16 was reduced from 25.18±17.29 to 7.59±6.79(P=0.001).Conclusion:Audit of current practice and the implementation of strategies to improve compliance with evidence-informed practice were effective and appeared to reduce the incidence and severity of common EGFRIsinduced skin toxicities.
出处 《中国护理管理》 CSCD 北大核心 2018年第2期282-287,共6页 Chinese Nursing Management
基金 复旦大学护理科研基金(FNF201657)
关键词 肿瘤 皮肤毒性 表皮生长因子受体抑制剂 皮疹 甲沟炎 干燥 临床审查 靶向治疗 tumour skin toxicity EGFRIs papulopustular rash paronychia fissures clinical audit targeted therapy
  • 相关文献

参考文献4

二级参考文献32

  • 1Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2): 92-98.
  • 2Kwak E. Ihe role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer. Oncologist, 2011, 16(11): 1498-1507.
  • 3Ku GY, Haaland BA, de Lima Lopes G Jr. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung Cancer, 2011, 74(3): 469-473.
  • 4Iyer R, Bharthuar A. A review of erlotinib-an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert Opin Pharmacother 2010, 11(2): 311-320.
  • 5Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol, 2011, 7(7): 817-825.
  • 6Metro Gj Crin6 L. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev Anticancer Ther, 2011, 11(5): 673-682.
  • 7Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.J Clin Oncol, 2010, 28(25): 3965-3972.
  • 8Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX- Lung 1): a phase 2b/3 randomised trial. Lancet Oncol, 2012, 13(5): 528-538.
  • 9Yang JC, Shih JY, Su wc, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol, 2012, 13(5): 539-548.
  • 10Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31(27): 3327-3334.

共引文献108

同被引文献66

引证文献5

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部